Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

CAPS Rating: 2 out of 5

The Company's mission is to discover, develop, and deliver to patients medicines for the treatment of cancer and related conditions.

Recs

1
Player Avatar zzlangerhans (99.77) Submitted: 6/28/2010 11:08:35 AM : Outperform Start Price: $6.09 INFI Score: +7.92

Not much inspiring news to report from the world of Infinity. So far retaspimycin has shown uninspiring results in GIST and now lung cancer. But with their substantial cash reserves and controlled burn rate I'm still willing to give them the benefit of the doubt, hoping for better data from the breast cancer trial in the near future. I'm also happy that they've broadened their pipeline by moving IPI-493 Hsp90 chaperone inhibitor into clinical trials.

Featured Broker Partners


Advertisement